Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting

被引：5
|
作者：
Hobbs, Miriam [1 ]
Paludo, Jonas [1 ]
Fonder, Amie [1 ]
Abeykoon, Jithma P. [2 ]
Gertz, Morie A. [1 ]
Rajkumar, S. Vincent [1 ]
Go, Ronald S. [1 ]
Buadi, Francis K. [1 ]
Lacy, Martha Q. [1 ]
Leung, Nelson [1 ]
Dispenzieri, Angela [1 ]
Gonsalves, Wilson I. [1 ]
Dingli, David [1 ]
Hwa, Yi L. [1 ]
Kourelis, Taxiarchis [1 ]
Kyle, Robert A. [1 ]
Kumar, Shaji [1 ]
Kapoor, Prashant [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Internal Med, Rochester, MN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3337.3337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3337
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma
    Garcia-Guinon, Antoni
    Charry, Paola Andrea
    Jimenez, Maria
    Sarra, Josep
    Delgado, Izarbe
    de la Torre, Laura Segura
    Santaliestra, Marta
    Garcia-Pintos, Marta
    Gonzalez, Yolanda
    Senin, Alicia
    Motllo, Cristina
    Abella, Eugenia
    Cabezudo, Elena
    Granell, Miquel
    Sancho, Esther
    Herranz, Maria Jose
    Seres, Yasmina
    Gironella, Mercedes
    Soler, Juan Alfons
    Marti-Tutusaus, Josep Maria
    Ben Azaiz, Ran
    de Larrea, Carlos Fernandez
    ANNALS OF HEMATOLOGY, 2025, 104 (02) : 1177 - 1186
  • [32] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
  • [33] Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    Usmani, Saad Z.
    Weiss, Brendan M.
    Plesner, Torben
    Bahlis, Nizar J.
    Belch, Andrew
    Lonial, Sagar
    Lokhorst, Henk M.
    Voorhees, Peter M.
    Richardson, Paul G.
    Chari, Ajai
    Sasser, A. Kate
    Axel, Amy
    Feng, Huaibao
    Uhlar, Clarissa M.
    Wang, Jianping
    Khan, Imran
    Ahmadi, Tahamtan
    Nahi, Hareth
    BLOOD, 2016, 128 (01) : 37 - 44
  • [34] Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
    Usmani, Saad
    Weiss, Brendan
    Bahlis, Nizar J.
    Belch, Andrew
    Lonial, Sagar
    Lokhorst, Henk
    Voorhees, Peter M.
    Richardson, Paul G.
    Sasser, A. Kate
    Axel, Amy
    Feng, Huaibao
    Uhlar, Clarissa
    Wang, Jianping
    Khan, Imran
    Ahmadi, Tahamtan
    Nahi, Hareth
    BLOOD, 2015, 126 (23)
  • [35] A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
    Rocchi, Serena
    Tacchetti, Paola
    Pantani, Lucia
    Mancuso, Katia
    Rizzello, Ilaria
    di Giovanni Bezzi, Chiara
    Scalese, Marco
    Dozza, Luca
    Marzocchi, Giulia
    Martello, Marina
    Barila, Gregorio
    Antonioli, Elisabetta
    Staderini, Michela
    Buda, Gabriele
    Petrini, Mario
    Cea, Michele
    Quaresima, Micol
    Furlan, Anna
    Bonalumi, Angela
    Cavo, Michele
    Zamagni, Elena
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 41 - 50
  • [36] Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
    Dimopoulos, M. A.
    Sonneveld, P.
    Siegel, D.
    Palumbo, A.
    San-Miguel, J.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2247 - 2256
  • [37] Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone
    Hagiwara, May
    Panjabi, Sumeet
    Sharma, Arati
    Delea, Thomas E.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 818 - 829
  • [38] Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience
    Byun, Ja Min
    Yoon, Sung-Soo
    Koh, Youngil
    Kim, Inho
    Jo, Jaemin
    Park, Hyunkyung
    Lee, Jeong-Ok
    Lee, Jiyun
    ANTICANCER RESEARCH, 2019, 39 (09) : 5165 - 5170
  • [39] Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Bahlis, Nizar
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea C.
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    Leblanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie Scott
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2019, 134
  • [40] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James
    Martinez, Daisy
    Spektor, Tanya
    Sanchez, Armando
    Ghermezi, Matthew
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E249 - E250
12345